

Prior Authorization Form

For cancer therapy: Gleevec (imatinib mesylate)



Sun Life Assurance Company of Canada, a member of the Sun Life Financial group of companies, is committed to keeping your information confidential.

1 Important – please read carefully

Please note that the completion of this form is not a guarantee of approval. It must be completed in full otherwise it will be returned to you. Any expense for medical evidence to support this request is your responsibility. Given the confidential nature of your information, we will issue our response to you in writing. If you have already purchased the medication for which you are requesting prior authorization, please attach all original receipts along with a regular extended health care claim form.

2 To be completed by plan member

Plan member information

| | | | | | |
|--|--|-----------------------------|------------|----------------------------|--|
| Contract number | | Member ID number | | Your plan sponsor/employer | |
| Your last name | | | First name | | <input type="checkbox"/> Male <input type="checkbox"/> Female |
| Your address (street number and name) | | | | | Date of birth (dd-mm-yyyy) — — |
| City | | | | | Province Postal code |
| Preferred language of correspondence <input type="checkbox"/> English <input type="checkbox"/> French | | Daytime phone number — — | | Fax number — — | |

Claimant information

| | | | |
|-----------------------------------|--|---|--|
| Claimant's last name | | First name | |
| Date of birth (dd-mm-yyyy) — — | | Relationship to plan member <input type="checkbox"/> Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child | |

Authorization and signature

I certify that the information I provided above is true and complete. I authorize Sun Life Assurance Company of Canada, its agents and service providers to collect, use and disclose information needed for underwriting, administration and adjudicating claims under this Plan with any person or organization who has relevant information pertaining to this application including health professionals, institutions, investigative agencies, insurers and reinsurers.

I agree that a photocopy or electronic version of this authorization shall be as valid as the original.

| | |
|------------------------------|--------------------------|
| Plan member's signature X | Date (dd-mm-yyyy) — — |
|------------------------------|--------------------------|



3 To be completed by prescribing physician

| | | | |
|--|----------|---------------------------|-------------------------|
| Prescribing physician's last name (please print) | | First name (please print) | |
| Specialty | | | Telephone number — — |
| Address (street number and name) | | | Apartment or suite |
| City | Province | Postal code | |
| Drug name | Strength | Dose | |

Gleevec (imatinib mesylate) will be eligible for reimbursement only if the patient satisfies one or more of the criteria listed below. If the patient does not satisfy any of the criteria, then the drug will not be eligible for reimbursement (please confirm by checking off the last box below). The eligible expense under this plan is that portion of the expense that is not payable or available under a government-sponsored drug program or another drug plan.

If approved, approval for coverage of this drug may be reassessed at any time at Sun Life Assurance Company of Canada's discretion.

Please indicate if the patient satisfies one or more of the following criteria:

- For the treatment of adult or pediatric patients with newly diagnosed, Philadelphia-chromosome-positive (Ph+), chronic myeloid leukemia (CML) in chronic phase.
- For the treatment of adult patients with Ph+ CML in blast crisis, accelerated phase or chronic phase (after failure of interferon-alpha therapy).
- For use as a single agent for induction phase therapy in adult patients with newly diagnosed Ph+ acute lymphoblastic leukemia (Ph+ ALL) or for adult patients with relapsed or refractory Ph+ ALL as monotherapy.
- For the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
- For the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SM-AHNMD) without the D816V c-Kit mutation. If c-Kit mutational status in patients with ASM or SM-AHNMD is not known or unavailable, treatment with Gleevec may be considered if there is no satisfactory response to other therapies.
- For the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR α rearrangement.
- For the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
- For the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
- For the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.

OR

- None of the above criteria applies.

Relevant additional information

| |
|--|
| |
|--|

| | |
|-----------------------------------|--------------------------|
| Physician's signature X | Date (dd-mm-yyyy) — — |
|-----------------------------------|--------------------------|

Respecting your privacy

Your privacy is important to us. We may leverage our strengths in our worldwide operations and in our negotiated relationships with third-party providers to help us service some of our customers. In some instances our employees, service providers, agents, reinsurers and any of their service providers, may be located in jurisdictions outside Canada, and your personal information may be subject to the laws of those foreign jurisdictions.

To find out about our Privacy Policy, visit our website at www.sunlife.ca, or to obtain information about our privacy practices, send a written request by email to privacyofficer@sunlife.com, or by mail to Privacy Officer, Sun Life Financial, 225 King St. West, Toronto, ON M5V 3C5.

Questions? Please visit www.sunlife.ca or call our toll-free number 1-800-361-6212
Monday - Friday, 8 a.m. - 8 p.m. ET

Mailing instructions – keep a copy for your records

Mail or fax your completed form to the claims office nearest you.

Fax number: 1-855-342-9915

Sun Life Assurance Company of Canada

PO Box 11658 Stn CV
Montreal QC H3C 6C1

Sun Life Assurance Company of Canada

PO Box 2010 Stn Waterloo
Waterloo ON N2J 0A6